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A major advantage of analyses on the food group level is that the results are better interpret-
able compared with nutrients or complex dietary patterns. Such results are also easier to
transfer into recommendations on primary prevention of non-communicable diseases. As
a consequence, food-based dietary guidelines (FBDG) are now the preferred approach to
guide the population regarding their dietary habits. However, such guidelines should be
based on a high grade of evidence as requested in many other areas of public health practice.
The most straightforward approach to generate evidence is meta-analysing published data
based on a careful deﬁnition of the research question. Explicit deﬁnitions of study questions
should include participants, interventions/exposure, comparisons, outcomes and study
design. Such type of meta-analyses should not only focus on categorical comparisons, but
also on linear and non-linear dose–response associations. Risk of bias of the individual stud-
ies of the meta-analysis should be assessed, rated and the overall credibility of the results
scored (e.g. using NutriGrade). Tools such as a measurement tool to assess systematic
reviews or ROBIS are available to evaluate the methodological quality/risk of bias of
meta-analyses. To further evaluate the complete picture of evidence, we propose conducting
network meta-analyses (NMA) of intervention trials, mostly on intermediate disease mar-
kers. To rank food groups according to their impact, disability-adjusted life years can be
used for the various clinical outcomes and the overall results can be compared across the
food groups. For future FBDG, we recommend to implement evidence from pairwise and
NMA and to quantify the health impact of diet–disease relationships.
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Background
Lifestyle is a crucial factor in the prevention of non-
communicable diseases. Large long-term prospective
cohort studies have shown that 60–75 % of coronary
events and 36 % of cancer incidences can be explained
by modiﬁable risk factors such as unhealthy diets,
overweight, obesity, physical inactivity, smoking and
excessive alcohol intake(1,2). According to the most
recent report by the global burden of disease (GBD)
2016 study, an unhealthy diet is a leading risk factor
for premature death and disability worldwide(3).
Dietary risk factors were associated with nearly 10 % of
the GBD(3).
Research to reduce dietary risk should address the level
of consumption of food groups in combination with
nutrients and other dietary compounds. A major advan-
tage of analyses on the food group level is that the results
are better interpretable compared with nutrients or
complex dietary patterns, and therefore easier to transfer
into recommendations on primary prevention of non-
communicable disease, including CVD, type 2 diabetes
(T2D), hypertension and different cancer types. A major
approach to reduce non-communicable diseases in a
population by modifying food intake is directly linked
to the concept of food-based dietary guidelines
(FBDG)(4,5). FBDG are the preferred approach to guide
the population regarding their dietary habits. However,
such guidelines should be based on a high grade of evi-
dence as requested in many other areas of public health
practice.
An adequate approach to clarify inconclusive data and
knowledge in the ﬁeld of public health nutrition is to sys-
tematically review and meta-analyse the published data
in order to further strengthen our understanding of the
interplay between lifestyle, diet and health(6). However,
the issue of quality of such systematic reviews with quan-
titative meta-analyses is getting more and more into the
focus. The widespread implementation of meta-analyses
is a novel phenomenon and the standards of its applica-
tion not always well known(7,8).
To close the gap between the evidence generated by
meta-analyses and the often direct transfer of such evi-
dence into recommendations, a careful implementation
of the systematic review and meta-analysis methods is
needed. This is particularly important for the dietary
recommendations such as the FBDG that often address
disease reduction as the aim.
Thus, in this paper, we will summarise the methodo-
logical background of meta-analyses with dietary vari-
ables, the evaluation of risk of bias and the methods to
assess the quality of evidence. The focus is given to
meta-analyses on food and food groups. We will also
highlight the evidence in this ﬁeld generated by
meta-analyses of randomised controlled trials (RCT)
with the new option of network analyses and the evi-
dence generated by observational studies. The concept
of disability-adjusted life year (DALY) will be proposed
as a method to quantify the food–disease relation across
various health outcomes and to rank the results in terms
of level of impact.
Generating the evidence for food-based dietary guidelines
General methodological background and standards of
meta-analyses
During past decades, the number of systematic reviews
with impact quantiﬁcation has remarkably increased and
they continue to replace narrative reviews previously
used to combine data from multiple studies. Narrative
reviews are often characterised by a lack of transparency
and are therefore inherently subjective(9). With the tremen-
dous increase of scientiﬁc publications(10), the method-
ology of narrative reviews has become less useful and
systematic approaches have become the preferred option.
Systematic reviews are described as comprehensive and
objective summaries of all relevant high-quality research
evidence addressing precise questions(11). In all ﬁelds of
health sciences including nutritional sciences, systematic
reviews have become an important tool for the evaluation
of intervention trials and the transfer of the results into
evidence-based science/medicine. The use of systematic
reviews and meta-analyses to investigate lifestyle-related
topics is also becoming increasingly popular due to the
accumulation of scientiﬁc data in the course of the past
years(12).
To avoid ﬂooding the media with poorly conducted
systematic reviews and meta-analyses, as already has
been criticised(7), researchers should comply with distinct
guidelines that ensure high-quality results when using this
technique.
The Cochrane handbook deﬁned ﬁve key characteris-
tics for systematic reviews(11): (1) A clearly stated set of
objectives with pre-deﬁned eligibility criteria for studies;
(2) An explicit, reproducible methodology; (3) A system-
atic search that attempts to identify all studies that would
meet the eligibility criteria; (4) An assessment of the val-
idity of the ﬁndings of the included studies, e.g. through
the assessment of risk of bias; (5) A systematic presenta-
tion and synthesis of the characteristics and ﬁndings of
the included studies.
Authors of systematic reviews andmeta-analyses ofRCT
are encouraged to follow the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses guidelines(13),
while the appropriate tool for systematic reviews and
meta-analyses of observational studies is the
Meta-analysis of Observational Studies in Epidemiology
checklist(14). The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses statement consists
of a twenty-seven-item checklist and a four-phase ﬂow dia-
gram. A particularly important Preferred Reporting Items
for Systematic Reviews and Meta-Analyses checklist
point includes an explicit statement of study questions
being addressed with reference to participants, interven-
tions/exposure, comparisons, outcomes and study design.
Table 1 demonstrates an example from a previously pub-
lished meta-analysis using the participants, interventions/
exposure, comparisons, outcomes and study design criteria
regarding the research question: Which dietary approach
offers the greatest beneﬁts in the management of glycaemic
control in T2D patients(15,16).
Systematic reviews are a form of observational research,
and the methods for the review should be agreed on before
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the review commences. Recording a detailed protocol of
each systematic review is an essential part of manuscript
submission now required by most peer-reviewed journals.
This can take the form of registration (e.g. at
PROSPERO – https://www.crd.york.ac.uk/PROSPERO/),
an open publication journal (e.g. BMJ Open or
Systematic Reviews) or a dated submission to a research
ofﬁce or research ethics board. Adherence to a well-
developed protocol reduces the risk of bias in the systematic
review. Other important items of the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses checklist
include: the presentation of full electronic search strategy of
at least one database; study selection process; data extrac-
tion process; assessment of risk of bias; description of meth-
ods to handle data and combine results; reporting of
evidence synthesis and additional analyses; summary of
the main ﬁndings and strength of the evidence; and report-
ing of sources of funding(13).
Statistical heterogeneity in a meta-analysis refers to
variations in study estimates between the included studies,
andmay be due to variability in the participants, interven-
tions, outcomes studied or methodological diversity. To
explore statistical heterogeneity between studies, the
Cochrane Q test and the I2 statistic are important formal
tests(11). Moreover, it is recommended to calculate the
95 % CI for the estimates of heterogeneity(17). A value
for I2 >50 % is considered to represent substantial hetero-
geneity(11). Important strategies to investigate the sources
of statistical heterogeneity include subgroup analysis (e.g.
by sex, age, length of follow-up, geographic location and
dietary assessment methods), meta-regression and sensi-
tivity analysis for low risk of bias studies.
Another important issue of meta-analyses are small
study effects, since smaller trials often report larger treat-
ment effects compared with larger trials. Publication bias
may be one of the reasons, since signiﬁcant results are
more likely submitted by authors and accepted by peer-
reviewed journals even if these results come from small
trials. Publication bias and small study effects can be
explored visually by checking funnel plot for symmetry
and by applying formal tests, including the Egger’s and
Begg’s test(11,18,19).
The observed effects in a study might be distorted by
dependencies that could arise when comparing several
treatment groups with one control group or several cat-
egories of exposures with one reference category. Such
within-study dependence of measures of effect should
be addressed in treatment comparisons and dose–
response analyses using approaches proposed for multi-
variate meta-analysis(20–22). However, adjustments for
such correlated measures of effect are often overlooked
in practice.
Speciﬁc features of meta-analyses of randomised
controlled trials
In RCT of dietary interventions the most common mea-
sures of effect are the absolute differences of the mean
value of a continuous outcome variable between two
groups (intervention group and control group). If studies
measure the outcome on different scales, the results have
to be standardised to a uniform scale and the standar-
dised mean difference has to be used(11).
In meta-analyses, the overall intervention effect is
summarised as weighted average of the (standardised)
mean difference of individual studies. Usually, a
random-effects model is used to combine the results,
with the underlying assumption that there is not only
one true effect size, but a distribution of true intervention
effects across studies. Differences in effect size may vary
by sex, age, geographic location, etc. If it is assumed that
individual studies are estimating one common true effect
size and differences are explained by sampling errors, a
ﬁxed-effect model is used(23). When there is clinical and
statistical heterogeneity, a random-effects model should
be the ﬁrst choice. In the random-effects model, the
true effect could vary from study to study. The
random-effects method and the ﬁxed-effect method will
give identical results when there is no statistical hetero-
geneity among the studies(11). Summary estimates with
their corresponding 95 % CI can be presented in a forest
plot(24).
RCT in nutrition research are often prone to inherent
methodological constraints. They sometimes cannot be
controlled with true placebos, but rather by a limitation
of certain aspects of nutrient compositions, food groups
or dietary patterns. Other limitations include the lack of
double blinding, poor compliance and adherence, cross-
over bias, and high drop-out rates. Failure of allocation
concealment, blinding and follow-up losses are well-
established limitations of RCT(25). Low-quality RCT
may lead to an overestimation of intervention effect esti-
mates and raise heterogeneity(26). Assessing the risk of
Table 1. Example for the application of the participants,
interventions/exposure, comparisons, outcomes and study design
criteria regarding the research question: Which dietary approach
offers the greatest beneﬁts in the management of glycaemic control
in type 2 diabetes (T2D) patients?(15,16)
Parameter Description
Participants Participants that are aged ≥18 years and are
diagnosed with T2D using the diagnosis
criteria of the American diabetes association
or other internationally recognised standards
Interventions/
exposure
Eligible types of intervention diets will be the
following:
Low-carbohydrate diet (carbohydrates provide
<30 % total energy intake, high intake of
animal and/or plant protein, often high intake
of fat); low-fat diet (fat provide <30 % of total
energy intake, high intake of cereals and
grains); vegetarian diet (no meat, poultry
and ﬁsh)
Comparison Control diet: no intervention or minimal
intervention
Outcome The primary outcome will be glycosylated Hb
(HbA1c); the following secondary outcomewill
be considered: fasting plasma glucose
Study design Randomised parallel or cross-over studies
comparing different dietary approaches with a
minimum intervention period of 3 months
L. Schwingshackl et al.434
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bias/study quality/study limitations of individual RCT
included in a meta-analysis is highly recommended, and
sensitivity analyses excluding high risk of biasRCT should
be conducted(11,13). The risk of bias tool by the Cochrane
collaboration takes the following items into account:
sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assess-
ment personnel, incomplete outcome and selective report-
ing. The riskof bias for each item is expressed simply as low
risk, high risk or unclear risk of bias(27). A previous ana-
lysis of ﬁfty randomly selected meta-analyses of RCT(28)
showed that 70 % applied the risk of bias assessment tool
by the Cochrane collaboration, 10 % the Jadad scale(29),
14 % reported no risk of bias/study quality/study limita-
tions item, 4 % applied their own score and one study
used the Rosendal scale(30).
A promising new evidence-synthesis method for inter-
vention studies is network meta-analysis (NMA), which
is an extension of pairwise meta-analysis that enables a
simultaneous comparison of multiple interventions,
forming a connected network while preserving the
internal randomisation of individual trials. NMA
combines direct (e.g. from trials comparing directly two
interventions) and indirect (e.g. from a connected root
via one more intermediate comparators) evidence in a
network of trials (Fig. 1)(31–33). For example, in Fig. 1,
none of the studies have compared intervention B
(whole grains) with intervention C (nuts), but each has
been compared with a common intervention A (reﬁned
grains), then we assume an indirect comparison of B
and C on the direct comparison of B and A and the direct
comparison of C and A. In this way, it enables inference
about every possible comparison between a pair of inter-
ventions in the network even when some comparisons
have never been evaluated in a trial. By conducting
NMA, it is possible to derive a relative ranking of the dif-
ferent intervention for each outcome using the distribu-
tion of the ranking probabilities and the surface under
the cumulative ranking curves(34). A fundamental
assumption of NMA, often called the transitivity
assumption, is that trials comparing different sets of
interventions should be similar enough in all characteris-
tics that may affect the outcome(35–37). To evaluate the
assumption of transitivity, the distribution of potential
effect modiﬁers (e.g. in Fig. 1, changes in body weight,
age, duration of diabetes) across the available direct com-
parisons should be compared. To evaluate the presence
of statistical inconsistency (i.e. disagreement between
the different sources of evidence), the loop-speciﬁc
approach (to detect loops of evidence that might present
important inconsistency)(38), as well as the side-splitting
approach (to detect comparisons for which direct esti-
mates disagree with indirect evidence from the entire net-
work)(39) should be applied.
Speciﬁc features of meta-analyses of cohort studies
Effect estimates in observational studies mostly refer to
binary or count outcomes (e.g. incidence of a disease, mor-
tality or prevalence) and are expressed mostly as hazard
ratios or OR as an estimate of relative risk. In nutritional
epidemiology, three types of meta-analysis regarding the
combination of estimates are recommended.
Usually, in a ﬁrst step, a high v. low meta-analysis is
conducted. Here, the summary risk estimate with the cor-
responding 95 % CI for a speciﬁc outcome (e.g. incidence
of a chronic disease) is calculated by comparing high v.
low intake of a single food or food group by applying
a random-effects model. As described earlier, the
random-effects model assumes that the true effect may
differ between studies and is more appropriate in nutri-
tional epidemiology. The natural logarithm of the risk
estimate is calculated for each study and weighted
according to the method of DerSimonian and Laird(40).
The high v. low meta-analysis provides an overview
about the average risk of high intake of a speciﬁc food
or food group compared with low intake regarding the
outcome of interest. One of the major limitations of
high v. low meta-analysis includes the comparability of
the level of exposure categories across studies because
intake categories generated in the original studies are
not always comparable between them.
Thus, meta-analyses should not solely focus on ‘sim-
ple’ high v. low analysis, but also examine the summary
effect for dose–response relations. In this analysis, the
association between a dietary factor, measured as a con-
tinuous variable, and risk of the outcome of interest is
investigated by performing a meta-analysis of the dose–
response relation from each study. If original studies do
not report on dose–response relations, the slope (linear
trend and 95 % CI) for each study can be estimated
using the method of generalised least squares for trend
estimation proposed by Greenland and Longnecker(21)
and implemented by Orsini et al.(41). In this case, infor-
mation on the risk estimates with corresponding 95 %
CI, the quantiﬁed exposure value and the distribution
of cases and person-years (or non-cases) is required for
at least three categories of the exposure. Missing infor-
mation on the distribution of person-years or non-cases
can be estimated if studies provide the number of total
cases in addition to total person-years or the number of
Fig. 1. (Colour online) Example of a network diagram. The size of
the nodes is proportional to the total number of participants
allocated to each dietary approach and the thickness of the lines
is proportional to the number of studies evaluating each direct
comparison. SSB, sugar-sweetened beverages.
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total participants plus follow-up period(42,43). If studies
report ranges of the exposure categories instead of the
mean value, the mid-point between the lower and
upper limits for each category can be calculated. For
open categories (e.g. the highest quantile), a similar
range to the adjacent category can be assumed.
Finally, to explore the shape of the diet–disease risk
association, a non-linear dose–response meta-analysis
can be performed for instance by using fractional
polynomial models, or restricted cubic spline regression
models(44,45). Non-linearity of the association can be
visually evaluated in graphs and by using a likelihood
ratio test(41).
Well-designed cohort studies provide important evi-
dence with complementary strength (decade long expo-
sures in large sample size of general populations with
hard endpoints) and limitations (residual confounding
and measurement error) as well. Ascertainment of expos-
ure, adjustment factors, assessment of outcome and
adequacy of follow-up are important challenges in con-
ducting these studies.
Similar to meta-analyses of RCT, assessment of the
risk of bias/study quality/study limitations of individual
cohort studies included in a meta-analysis is import-
ant(14). A previous analysis of ﬁfty randomly selected
meta-analyses of cohort studies(28) showed that 40 % of
these meta-analyses applied no quality assessment score
and 38 % used the Newcastle Ottawa Scale (points
range 0–9), while the remaining 22 % applied a variety
of less well-known tools(46).
Recently, we proposed a risk of bias assessment of
cohort studies that takes into account ascertainment of
exposure such as usual dietary intake, adjustment factors,
assessment of outcome and adequacy of follow-up(28):
Usual dietary intake (e.g. long-term average) cannot
usually be observed directly. Hence, in nutritional stud-
ies, dietary intake is mostly assessed by self-report instru-
ments. The most prominent assessment instruments are
FFQ, food record, 24 h dietary recall and dietary
screener. All self-report dietary assessment instruments
are prone to different types of measurement error and
therefore can lead to biased risk estimates and loss of
power(47). The risk of bias depends on the applied dietary
assessment instrument, which is determined by the study
design and study aim. In our risk of bias assessment tool,
we proposed a low risk of bias rating for validated and
calibrated FFQ, multiple 24 h dietary recalls and food
records. Conversely, non-validated FFQ and single 24 h
dietary recalls should be rated with a high risk of bias(28).
A useful overview and description of the applicability of
most prominent dietary assessment instruments is given
in the Dietary Assessment Primer(48). In cohort studies,
covariate adjustment is done to address confounding
and other sources of bias (e.g. selection bias) or to
increase precision in a diet–health outcome model.
Therefore, the choice of an adequate set of adjusting
variables depends on the assumed relationship between
the exposure, the outcome and adjusting variables as
well as the purpose of the statistical analyses. As in nutri-
tional observational studies many confounding factors
are often assumed to be present, we simpliﬁed the risk
of bias by counting the number of adjusting variables,
rating low risk of bias for models with two or more
adjusting variables. This simpliﬁcation is based on the
assumption that the adjustment variables of the studies
that have been carried out are reasonable. It is important
to remind that different adjustment sets can lead to dif-
ferent study results. A cohort study is rated with a low
risk of bias for the assessment of outcome if the study
provides record linkage (International Classiﬁcation of
Diseases codes), accepted clinical criteria or if assessment
was blinded or independent. Conversely, self-reported
and no assessment of study outcomes was rated as having
a high risk of bias. Taking into account adequacy of
follow-up we recommend for a rating of low risk of
bias, a median follow-up of, e.g. ≥10 years for CVD,
and ≥5 years for T2D.
Credibility of the evidence within meta-analyses
We recently developed the NutriGrade scoring system
(maximum of ten points), to evaluate the trustworthiness
(credibility) of evidence for the effect/association of a
dietary factor and the outcome of interest(28).
Compared with the well-established Grading of
Recommendations Assessment, Development and
Evaluation approach, NutriGrade differs in the follow-
ing aspects: it gives more weight to the evaluation of
cohort study designs, because such design is important
for the investigation of diet–disease relations; it assesses
nutrition-speciﬁc aspects, such as dietary assessment
methods and their validation, calibration of FFQ, and
the assessment of diet-associated biomarkers; ﬁnally, it
also considers the conﬂict of interest and funding bias
as a separate item.
NutriGrade is based on the following seven items for
RCT: (1) risk of bias, study quality, study limitations
(maximum 3 points); (2) precision (maximum 1 point);
(3) heterogeneity (maximum 1 point); (4) directness
(maximum 1 point); (5) publication bias (maximum 1
point); (6) funding bias (maximum 1 point); (7) study
design (+2 points); and the following eight items for
cohort studies: (1) risk of bias, study quality, study lim-
itations (maximum 2 points); (2) precision (maximum 1
point); (3) heterogeneity (maximum 1 point); (4) direct-
ness (maximum 1 point); (5) publication bias (maximum
1 point); (6) funding bias (maximum 1 point); (7) effect
size (maximum 2 points); and (8) dose–response relations
(maximum 1 point).
To evaluate and interpret the meta-evidence, we rec-
ommend four categories based on this scoring system:
high conﬁdence in the effect estimates (≥8 points); mod-
erate conﬁdence in the effect estimates (6 to <8 points);
low conﬁdence in the effect estimates (4 to <6 points);
very low conﬁdence in the effect estimates (0 to <4
points).
There is also a need to evaluate the credibility of NMA
evidence in a systematic way. The conﬁdence in NMA
(http://cinema.ispm.ch/) framework has been developed
to judge the conﬁdence that can be placed in the results
obtained from a NMA by adapting and extending the
Grading of Recommendations Assessment, Development
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and Evaluation approach domains (study limitations,
inconsistency, indirectness, imprecision and publication
bias). The system is transparent and applicable to any net-
work structure(49).
Evaluating the methodological quality of meta-analyses
AMSTAR, a measurement tool to assess systematic
reviews, is one of the most widely used instruments to
assess the methodological quality of systematic reviews,
and consists of eleven-item questionnaire (e.g. provision
of an a priori design, use of two independent reviewers
for data extraction, assessment and documentation of
study quality, assessment of publication bias, conﬂict of
interest statement) that asks reviewers to answer yes, no
or can’t answer, and was published in 2007 (maximum
score of 11)(50). An umbrella review of fourteen
meta-analyses investigating the impact of nut intake on
biomarkers of CVD showed that ten out of fourteen
reported an AMSTAR score <8(51). Two recent over-
views of reviews suggest that current meta-analyses/sys-
tematic reviews evaluating the association of
Mediterranean diet on health ouctomes varied strongly
regarding their methodologic quality (total score 4–20),
assessed with a modiﬁed AMSTAR quality scale (max-
imum score 22)(52,53). Recently, an update of the
AMSTAR has been published (AMSTAR 2). This
update is based on sixteen items and has an overall rating
based on weaknesses in critical domains(54).
A new tool for assessing the risk of bias in systematic
reviews (the ROBIS tool) mainly covers research ques-
tions relating to effectiveness, aetiology, diagnosis and
prognosis(55). Important ﬂaws and limitations in the
design, conduct or analysis of a systematic review will
inﬂuence the results or conclusions of the review. It is
important to note that a systematic review can be judged
with a low risk of bias, even if the included studies were
rated with a high risk of bias, as long as the systematic
review has rigorously assessed the risk of bias of the
included studies when summarising the evidence. The
tool includes three phases: the ﬁrst focuses on the rele-
vance of the research question (deﬁne the participants,
interventions/exposure, comparisons, outcomes and
study design criteria) (which is optional); the second eval-
uates potential bias (study eligibility criteria, identiﬁca-
tion and selection of studies, data collection and study
appraisal, and synthesis and ﬁndings of the review pro-
cess) and in the third phase, the risk of bias is judged(55).
Quantiﬁcation of health impact of diet–disease relations
Given the multi-facetted nature of population health, the
health impact or burden of disease and risk factors can
be described by a variety of indicators(56). Typical health
impact indicators include cause-speciﬁc mortality rates,
incidence rates and prevalence ratios. These metrics how-
ever do not allow for a comprehensive comparison or
aggregation of health outcomes. Indeed, these unidimen-
sional measures of population health only quantify the
effects of either mortality or morbidity, thus impeding
comparisons between fatal and disabling conditions.
Furthermore, they only take into account disease
occurrence, without quantifying disease severity. In
response to these limitations, several authors have
developed summary measures of population health that
integrate multiple dimensions of health impact. Driven
by the inﬂuential GBD studies, led by the WHO and the
Institute for Health Metrics and Evaluation, the DALY
has become the key summary measure of population
health for quantifying burden of disease(57,58). The
DALY is a health gap measure, quantifying the health
gap from a life lived in perfect health as the number of
years of healthy life lost due to illness (years lived with
disability, YLD) and premature death (years of life lost,
YLL):
YLD= number of incident cases × duration until
remission or death × disability weight,
YLL = number of deaths × residual life expectancy at
the age of death.
An alternative formula for calculating YLD follows an
incidence rather than a prevalence perspective(59):
YLD= number of prevalent cases × disability weight.
Two complementary approaches may be deﬁned for
quantifying the disease burden associated with dietary
or other risk factors(60). In the bottom-up approach,
dose–response relations of dietary exposure and health
outcomes are combined in a risk assessment model to
predict the expected disease burden(61). The top-down
approach starts from available epidemiological data
and associates health states with the concerned risk fac-
tor at an individual level (e.g. categorical attribution)
or at a population level (e.g. comparative risk assess-
ment). In the GBD studies, comparative risk assessment
is the standard approach for quantifying diet-related
health problems(3,62,63). This approach is based on the
calculation of population-attributable fractions (PAF),
which represent the proportion of risk that would be
averted if exposure would have been limited to an ideal
exposure level. Estimates of the attributable burden
(AB) for risk–outcome pairs are obtained by multiplying
the overall burden estimate with the PAF:
AB =DALY× PAF.
The PAF for a continuous risk factor, such as consump-
tion of fruit and vegetables quantiﬁed in terms of g/d, is
deﬁned as follows:
PAF =
NameMeu
x=l RR(x)P(x)dx−RR(TMREL)NameMeu
x=l RR(x)P(x)dx
,
where RR(x) is the relative risk as a function of exposure
level x, which ranges between a lower bound l and an
upper bound u; P(x) is the prevalence of exposure at
level x; and TMREL is the theoretical minimum-risk
exposure level.
In a similar way, the PAF for a discrete risk factor
which can take on u different distinct exposure levels,
such as consumption of fruit and vegetables quantiﬁed
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as speciﬁc consumption levels, is deﬁned as:
PAF =
∑u
x=1 RR(x)P(x) −RR(TMREL)∑u
x=1 RR(x)P(x)
.
The most recent iteration of the GBD project is the GBD
2016, which provides estimates for the period 1990–
2016(3,63). By providing estimates on the burden of
dietary risk factors, the GBD project allows for a direct
identiﬁcation and ranking of diet-related health problems
at a global, regional or national level(3,63). The GBD
2016 estimates can be explored in an interactive way
via http://vizhub.healthdata.org/gbd-compare/.
According to the GBD 2016 study, dietary risk factors
were associated with nearly 10 % of the GBD. The major
diet-associated disease clusters were CVD (8·0 % of total
DALY), diabetes (1·0 % of total DALY) and neoplasms
(0·6 % of total DALY). The group of dietary risk factors
comprised ﬁfteen individual dietary risks, with diets low
in whole grains and diets low in fruit as major contribu-
tors (Fig. 2).
In this context, attention should be given to the poten-
tial dependencies between measures of effect/association
if the overall impact of an exposure, e.g. a food, is com-
pared across health outcomes. For example, a certain
food group (exposure) having an impact on multiple,
dependent health outcomes such as mortality and
CVD, where CVD also contributes to mortality itself.
The current meta-analyses aggregate the study results
for a single outcome and assume that the measured
effect/association are independent across all health out-
comes(64). However, this assumption is not realistic and
it can be assumed that health outcomes correlate with
each other(65). It could be shown that correlations
between health outcomes result in dependences between
measures of effect/association across health outcomes
that could lead to biased estimates(66), underestimated
standard error of the effect estimate (leading to narrow
CI) and incorrect rejection of the null hypothesis(67).
A number of approaches have been proposed to
meta-analyse dependent effect sizes. If the correlations
between effect sizes are available, the dependence
can be mathematically modelled using approaches
proposed by means of a multivariate model for the
meta-analysis(20,68–70). However, as correlations among
measurements of effect are not often reported in the stud-
ies, a meta-analysis using a multi-variate approach may
be challenging. Alternatively, a three-level meta-analysis
can be used when correlations between the measurements
of effect are not known(71,72). A three-level meta-analysis
is the extension of the two-level meta-analysis in which
the within-study-dependent effect sizes are clustered at
level 2 and the between-study effects are estimated at
level 3. Other possible approaches when correlations
among effect estimates are not known include robust
variance estimation(73) and methods of moments(74,75).
Many of these approaches are available in the statistical
software package R(64,76,77).
Current evidence for food-based dietary guidelines
Meta-analyses of randomised controlled trials
Compared with the tremendous number of published
meta-analyses of observational studies on the association
between food groups and risk of chronic diseases, the num-
ber of meta-analyses of RCT investigating the effect of
food groups on metabolic risk factors is very low.
Although very large long-termRCThave been conducted,
e.g. the Women’s Health Initiative Dietary Modiﬁcation
Trial or the Prevención con Dieta Mediterránea
trial(78,79), most dietary intervention studies are of short-
termdurationwith small sample sizes, and focus ondietary
approaches (e.g. low-carbohydrate diet, Mediterranean
diet), and/or dietary supplements (e.g. vitamins, minerals)
often in high-risk populations, and did not often investi-
gate the effects of single-food groups. Nevertheless, some
meta-analyses on the effects of food groups on cardiovas-
cular risk factors have been published (Table 2).
A meta-analysis of twenty-four RCT showed that the
consumption of whole-grain diets compared with control
diets reduces LDL-cholesterol (LDL-C) and total choles-
terol (TC), but not HDL-cholesterol (HDL-C) or
TAG(80), whereas other meta-analyses showed a reduction
in fasting glucose (FG), but no effect on diastolic blood
pressure and systolic blood pressure (SBP), respectively,
or body weight(81,82). A Cochrane review of ten RCT
Fig. 2. (Colour online) Contribution of dietary risk factors to the global burden of disease, 2016. DALY,
disability-adjusted life years.
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focusing on interventions to increase fruit and vegetable
consumption showed reductions in diastolic blood pres-
sure, SBP and LDL-C, but analyses were based on only
two trials(83). Other meta-analyses reported no effect on
HDL-C, TAG, FG or body weight(84,85). Meta-analyses
investigating the effects of nut consumption reported
reductions in TC, LDL-C, TAG, diastolic blood pressure,
FG and glycosylated Hb (both in T2D patients)(86–88), but
no effects on body weight, HDL-C, SBP and C-reactive
protein(87,89,90). Focusing on legumes, one meta-analysis
of ten RCT indicated that interventions to increase the
intake of legumes were associated with decreased TC
and LDL-C levels compared with a control group(91),
others reported reductions in C-reactive protein, SBP
and FG(92,93), but no effects on body weight(92).
Evidence from meta-analyses of intervention trials
showed that higher consumption of sugar-sweetened bev-
erages (SSB) leads to a considerable increase in body
weight(94,95).
Considering food groups of animal origin, higher con-
sumption of eggs increased TC, LDL-C and HDL-C,
but not TAG compared with control diets low in egg con-
sumption(96). A meta-analysis of RCT showed that higher
dairy intake has no signiﬁcant effect on change in SBP for
interventions over 1–12 months(97), and other
meta-analyses showed no signiﬁcant effects of either
high- or low-fat dairy products on cardiovascular risk fac-
tors and body weight compared with a diet with lower
amount of dairy(98,99). A recent meta-analysis showed
that there is evidence indicating that consuming oily ﬁsh
leads to signiﬁcant improvements in two important bio-
markers of cardiovascular risk, such as TAG and
HDL-C, whereas no effects were observed for TC,
LDL-C, diastolic blood pressure, SBP, FG and
C-reactive protein(100). Regarding meat intake, consump-
tion of more than a half serving of total red meat daily
does not inﬂuence blood lipids and lipoproteins or blood
pressure compared with lower red meat intakes(101).
Meta-analyses of cohort studies
A series of dose–response meta-analyses investigated the
association between twelve a priori-deﬁned food groups
and risk of all-cause mortality, CHD, stroke, heart
failure, T2D, colorectal cancer and hypertension
(Table 3)(102). The meta-analysis for all-cause mortality
included 100 cohort studies, and showed that higher
intakes of whole grains, vegetables, fruit, nuts and ﬁsh
were associated with lower risk of premature death,
whereas higher intakes of red and processed meat and
SSB were associated with higher overall mortality risk
in the linear dose–response meta-analysis(103). Focusing
on T2D, the optimal consumption of risk-decreasing
foods (two servings/d whole grains; two to three ser-
vings/d vegetables; two to three servings/d fruit; three
servings/d dairy) resulted in a 42 % reduction of T2D
risk, and consumption of risk-increasing foods (one serv-
ing/d eggs, two servings/d red meat, four servings/d pro-
cessed meat and three servings/d SSB) was associated
with a 3-fold T2D risk, compared with non-consumption
of these food groups(104). Regarding CVD, 123 cohort
studies were identiﬁed. An inverse association was pre-
sent for whole grains, vegetables and fruit, nuts and
ﬁsh consumption, while a positive association was pre-
sent for egg, red meat, processed meat and SSB con-
sumption in the linear dose–response meta-analysis(105).
Taking into account twenty-eight reports investigating
the association between the twelve food groups and the
risk of hypertension, we could show that optimal intakes
of whole grains, fruit, nuts, legumes and dairy were asso-
ciated with a 44 % risk reduction, whereas high con-
sumption of red and processed meat and SSB was
related with a 33 % increased risk of hypertension(106).
Eighty-six cohort studies were included in the
meta-analysis investigating the association between the
twelve food groups and colorectal cancer risk. Optimal
consumption of risk-decreasing foods (six servings/d
whole grains, vegetables and dairy; and three servings/d
fruit) results in a 56 % risk reduction of colorectal cancer,
whereas consumption of risk-increasing foods of two ser-
vings/d red meat and four servings/d processed meat was
associated with a 1·8-fold increased risk(107). Previous
meta-analyses of cohort studies comparing high v. low diet-
ary intake reported a signiﬁcant lower risk of weight gain
for higher intake of whole grain products(81) and a lower
risk of adiposity for higher intake of fruit and vegetables
Table 2. Evidence summary from meta-analyses of intervention trials investigating the effects between food groups and metabolic risk
factors(80–101)
Body weight
Total
cholesterol
LDL-
cholesterol
HDL-
cholesterol TAG DBP SBP
Fasting
glucose HbA1c CRP
Whole grains ↔ ↓ ↓ ↔ ↓ ↔ ↔ ↓ NA NA
Fruit and vegetables ↔ ↔ ↓ ↔ ↔ ↓ ↓ ↔ NA NA
Nuts ↔ ↓ ↓ ↔ ↓ ↔ ↓ ↓ ↓ ↔
Legumes ↓ ↓ ↓ ↔ ↔ ↔ ↓ ↓ NA ↓
Eggs NA ↑ ↑ ↑ ↔ NA NA NA NA NA
Dairy ↔ NA ↔ ↔ NA ↔ ↔ NA NA ↔
Fish NA ↔ ↔ ↑ ↓ ↔ ↔ ↔ NA ↔
Red meat NA ↔ ↔ ↔ ↔ ↔ ↔ NA NA NA
Sugar-sweetened beverages ↑ NA NA NA NA NA NA NA NA NA
CRP, C-reactive protein; DBP, diastolic blood pressure; HbA1c, glycosylated Hb; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; NA, not assessed; SBP,
systolic blood pressure.
↔ No effect with increased intake; ↑ increased with higher intake; ↓ reduction with increased intake.
Generating evidence for diet-disease relation 439
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0029665118000125
Downloaded from https://www.cambridge.org/core. IP address: 81.11.161.40, on 17 Nov 2018 at 09:28:58, subject to the Cambridge Core terms of use, available at
and dairy(108,109). Another meta-analysis of observational
studies reported consistent evidence that both red and pro-
cessed meat intake was positively associated with the risk of
obesity(110). Consistent evidence from another
meta-analysis of cohort studies showed that high consump-
tion of SSB is associated with a higher risk of weight
gain(94).
Credibility of the evidence
Table 3 gives an overview of the NutriGrade judgement
on the association between intake of food groups and
the risk of chronic diseases derived from meta-analyses
of cohort studies(103–107). The credibility of evidence was
rated high for the inverse association between whole
grain intake and the risk of all-cause mortality and
T2D, as well as for the positive association between red
meat, processed meat and SSB and the risk of T2D. For
these associations, further research probably will not
change our conﬁdence in the estimates. Most of the evi-
dence for the associations between the twelve food groups
and chronic disease risk is based on low and moderate
quality of evidence, and further research could provide
or add (important) evidence.
Conclusions
FBDG are the preferred approach to guide the population
regarding their dietary habits, and such guidelines should
be based on a high grade of evidence as requested in many
other areas of public health practice. The most straightfor-
ward approach to generate evidence is meta-analysing pub-
lished data based on a careful phrasing of the research
question (participants, interventions/exposure, compari-
sons, outcomes and study design). Hereby, it is important
to generate evidence by applying meta-analytical methods
to both major study designs (RCT and cohort studies).
Regarding credibility of evidence assessment, risk of bias
and other characteristics of the meta-analyses should be
assessed, rated and scored (NutriGrade).
Evidence from large meta-analyses of cohort studies
suggest that higher intake of plant origin food groups
such as whole grains, fruit, vegetables, nuts and legumes
are associated with a lower risk of chronic diseases,
whereas higher intake of red and processed meat and
SSB are associated with increased risk of T2D, CVD
and hypertension. Although the evidence from
meta-analyses of RCT is much more incomplete, it was
shown that several food groups such as whole grains,
fruit and vegetables, nuts, legumes and ﬁsh had a beneﬁ-
cial effect on the cardio-metabolic risk proﬁle. To further
contribute to the evaluation of the complete picture of
FBDG, we propose conducting NMA of RCT considering
and rating different food groups in one analysis.
Moreover, the health impact of the different foods can
be calculated by DALY for the various clinical outcomes
and the overall results compared across the food groups
and across approaches that consider the correlations
between health outcomes. For future FBDG, we recom-
mend to implement evidence from pairwise and NMA
and to quantify the health impact of diet–disease
relationships.
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Table 3. Evidence summary frommeta-analyses of cohort studies investigating the association between twelve food groups and the risk of major
chronic disease(81,94,102–110)
All-cause
mortality CHD Stroke
Heart
failure
Type 2
diabetes Hypertension
Colorectal
cancer
Overweight/obesity/
weight gain
Whole grains (per 30 g/d) *
Reﬁned grains (per 30 g/d) NA NA
Vegetables (per 100 g/d) *
Fruit (per 100 g/d) *
Nuts (per 28 g/d) NA
Legumes (per 50 g/d) NA NA
Eggs (per 50 g/d) NA
Dairy (per 200 g/d) *
Fish (per 100 g/d) NA
Red meat (per 100 g/d) *
Processed meat (per 50 g/d) *
Sugar-sweetened beverages
(per 250 ml/d)
(per 330 ml/d)
*High v. low analysis; no association between food group intake and chronic disease; ↑ increased risk with higher intake; decreased risk with higher intake;
NA, not assessed. The thickness of arrows corresponds to the quality of evidence: / = high; / = moderate; / = low; / = very low.
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